Archive for category The Pharmaceutical Industry

Maker of Hepatitis C Drug Strikes Deal on Generics for Poor Countries

The New York Times, 15 September 2014
Author: Gardiner Harris
“The maker of one of the costliest drugs in the world announced on Monday that it had struck agreements with seven Indian generic drug makers to sell lower-cost versions of the medicine — a $1,000-a-pill Hepatitis C treatment — in poorer countries”.
Find article here.


Doctors and pharmacists call for tighter controls on codeine due to rise in addiction

SMH, 14 September 2014
Author: Rachel Browne
“Doctors and pharmacists are calling for tighter controls on medicines containing codeine due to increasing concern about addiction, with users being referred to drug programs – including methadone – for treatment.”
Find article here.

Birth Control Pills Should Be Available Over The Counter, But That’s No Substitute For Contraceptive Coverage

Health Affairs Blog, online 10 Sept, 2014
Authors: Adam Sonfield and Sneha Barot
“In recent weeks, some opponents of the Affordable Care Act’s (ACA) contraceptive coverage guarantee have promoted the idea that oral contraceptive pills should be available to adult women without a prescription. Sens. Kelly Ayotte (R-NH) and Mitch McConnell (R-KY), for example, recently introduced the so-called Preserving Religious Freedom and a Woman’s Access to Contraception Act, a bill that would urge the Food and Drug Administration (FDA) to study whether to make contraceptives over the counter (OTC) — though for adults only.”
Find article here.

Big pharmacies knock on door of oil-rich North Dakota

Reuters, 4 September 2014
Author: Ernest Scheyder
“North Dakota’s oil boom has fueled a construction bonanza for new supermarkets, restaurants and clothing stores. But try finding a national pharmacy chain in the state, and you’ll be largely out of luck.”
Find article here.

NHS England push to rein in cancer drug prices

BBC, 27 August 2014
Author: Chris Cook
“The government is set to threaten to stop buying some expensive cancer drugs if manufacturers do not cut their prices, Newsnight has learned.”
Find article here.

Forced switch? Drug cos. develop maneuvers to hinder generic competition

CBS, 28 August 2014
Author: Jonathan Lapook
“An Alzheimer’s medication called Namenda is due to go generic next year. The company that makes Namenda, plans to stop the sale of the version at least six months before a less expensive, generic product could become available. A newer form, one that has additional patent protection, is unlikely to go generic for years”
Find article here.

National Health Amendment (Pharmaceutical Benefits) Bill 2014 [Provisions]: inquiry report

Community Affairs Legislation Committee, senate, Commonwealth of Australia, 27 August 2014
“Key provisions of the Bill
“1.12   The Bill is comprised of five schedules, each containing provisions with staggered commencement dates over the period 2015–2019:
“1.13      The Bill includes measures that:

  • increase co-payments by $5.00 for general patients and by 80 cents for concessional card holders, with effect from 1 January 2015;[8]
  • increase the concessional safety net threshold by two prescriptions each year for four years, from 2015 to 2018;[9] and
  • increase the general patient safety net threshold by 10 per cent each year for four years, from 2015 to 2018.[10]“

Find full report here.

Do we need a law to help people try experimental drugs?

The Conversation, online 26 August 2014
Author: Tina Cockburn, Bill Madden
“People with life-threatening or incurable diseases may be willing to try experimental drugs and unproven treatments, but they face the risk of exploitation. Is the law the best avenue to ensure that they…”
Find article here.

Marijuana strains doctor-patient relationship

CMAJ August 25, 2014 cmaj.109-4879
Author: Laura Eggerton
“New federal regulations that cast doctors as the “gatekeepers” to medical marijuana have increased pressure on them to authorize access to what is effectively an unproven drug, the head of the Canadian Medical Association (CMA) has told delegates to its annual meeting. “It puts physicians in a very awkward situation and it strains the physician-patient relationship,” CMA President Dr. Louis Hugo Francescutti told reporters at an Aug. 18 news conference in Ottawa. “It’s just plain bad medicine to prescribe a product when we don’t know how it works, we don’t know when it works, who it works for, how it interacts or how much to prescribe….””
Find article here.

Pharmaceutical industry code of conduct fails to find favour

The Conversation, online 22 August 2014
Author: Ken Harvey
“The Australian Competition and Consumer Commission (ACCC) is considering whether to approve the latest Medicines Australia code of conduct for pharmaceutical companies. The code lays out disclosure requirements for payments and other transfers of value (payment for sitting on drug company advisory boards; air-fares, accommodation and conference registration fees; funds for drug company-sponsored lectures). … The ACCC received 45 submissions about the draft and they tell an interesting story: a large number, from individuals and organisations alike, oppose the code.  Indeed, some of the submissions are positively furious.”
Find article here.